The estimated Net Worth of Mitchall G. Clark is at least $6.88 Million dollars as of 18 May 2018. Mitchall Clark owns over 25,860 units of Atara Biotherapeutics Inc stock worth over $897,247 and over the last 10 years Mitchall sold ATRA stock worth over $5,986,031.
Mitchall has made over 17 trades of the Atara Biotherapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mitchall sold 25,860 units of ATRA stock worth $1,293,776 on 18 May 2018.
The largest trade Mitchall's ever made was selling 100,203 units of Atara Biotherapeutics Inc stock on 27 March 2018 worth over $3,794,688. On average, Mitchall trades about 10,493 units every 42 days since 2014. As of 18 May 2018 Mitchall still owns at least 107,972 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Mitchall Clark stock trades at the bottom of the page.
Mitchall's mailing address filed with the SEC is 611 Gateway Blvd #900, South San Francisco, CA 94080, USA.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier, and Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: